Page last updated: 2024-09-03

ly 293558 and Neurodegenerative Diseases

ly 293558 has been researched along with Neurodegenerative Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP	1

Other Studies

1 other study(ies) available for ly 293558 and Neurodegenerative Diseases

Article	Year
The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:2 Topics: Animals; Chemical Warfare Agents; Electroencephalography; gamma-Aminobutyric Acid; Interneurons; Isoquinolines; Neurodegenerative Diseases; Neurons; Rats; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles	2011

Article

Year

The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.

The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:2

Topics: Animals; Chemical Warfare Agents; Electroencephalography; gamma-Aminobutyric Acid; Interneurons; Isoquinolines; Neurodegenerative Diseases; Neurons; Rats; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles

2011